G

GSK

Develops medicines, vaccines, and consumer health

Patient Access Manager

Full-Time
$152.3k - $253.8k/yr+ Annual bonus + Share-based long-term incentive program
Mid
Bachelor's, MBA, PharmD, Bachelor of Science (BS)
Camelback East Village, Phoenix, AZ, USA+9 moreMore locations: Mesa, AZ, USA | Central City, Phoenix, AZ, USA | Flagstaff, AZ, USA | Scottsdale, AZ, USA | Phoenix, AZ, USA | Chandler, AZ, USA | San Diego, CA, USA | Tucson, AZ, USA | Glendale, AZ, USA
Remote
Medical, Clinical & VeterinaryClinical Support & Patient Administration

About the job

Requirements
  • A bachelor's degree is required.
  • At least 3 years of combined experience in field reimbursement, hub case management, patient experience programs, or helping patients and providers navigate insurance verification, prior authorization requirements, and access criteria is required.
  • Ability to travel up to 20%, including overnight travel.
  • A valid driver's license is required.
  • Candidates should reside within the assigned territory or within 30 miles of the territory border.
  • Extensive experience in oncology patient navigation, access and reimbursement, or hub case management is preferred.
  • An advanced degree, such as an MBA, MPH, PharmD, or another relevant clinical or business degree, is preferred.
  • An active registered nurse license and a Bachelor of Science in Nursing are preferred.
  • Experience using customer relationship management and case-management platforms, preferably Salesforce Health Cloud, to document interactions, manage cases, and maintain accurate records, is preferred.
  • Verbal, written, and presentation communication skills are preferred.
  • The role includes the listed skills: Data to Insights, Digital Fluency, Market Access Strategies, Matrix Leadership, Payer Evidence, Pricing Strategies, and Scientific Literacy.
Responsibilities
  • Serve as the point of contact for patients, caregivers, and healthcare provider office staff, providing approved information and education on oncology-specific care, including benefit discussions, product and disease-state information per the Prescribing Information, and program-specific resources.
  • Conduct welcome calls and ongoing patient-journey touchpoints, discuss the end-to-end patient experience within program specifications, and use approved call guides, frequently asked questions, and Prescribing Information.
  • Support patient enrollment in GSK services, including patient assistance programs, and guide patients and offices through enrollment requirements, missing information, and consent capture.
  • Provide program-specific treatment education using approved call guides, and offer Important Safety Information and Prescribing Information whenever product education is delivered.
  • Educate patients on coverage outcomes, cost-sharing, and financial assistance options, including publicly available information on alternate coverage and independent foundations within program rules.
  • Facilitate transfers to specialty pharmacies, Medical Information, the GSK Response Center, Risk Evaluation and Mitigation Strategy vendors, and back-office Benefits Specialists for benefit investigation, benefit verification, and prior authorization tracking when appropriate.
  • Conduct all patient communication through approved recorded telephony and program systems, verifying patient identifiers and consent status before each interaction.
  • Maintain accurate documentation of activities and interactions within GSK's internal system.
  • Capture and report adverse events and product quality complaints within required timeframes and follow crisis-management procedures.
  • Adhere to company policies and procedures, compliance guidance, and policies applicable to federal, state, and local regulations.
  • Ensure activities align with Health Insurance Portability and Accountability Act privacy requirements and internal compliance guidelines.
  • Educate provider offices on payer coverage, coding, and payment policies for GSK Oncology products using approved materials, and help offices understand and use GSK Patient Support Programs.
  • Support access case resolution at the office level by explaining benefit investigation outcomes, prior authorization requirements and processes, and appeal pathways; the office initiates and submits all payer forms.
  • Identify access and reimbursement barriers and escalate complex, systemic, or technical payer issues to the specialist access function and leadership.
  • Interface with Payer Account Managers, Specialty Pharmacy Account Directors, and Oncology Sales teams within the boundaries of the PAN Standard and program ways of working.
  • Document all interactions and manage cases in Salesforce Health Cloud or the customer relationship management system in line with program standards.
  • Follow standard operating procedures and business rules consistently, and complete training on corporate policies governing access to confidential data on time.
  • Maintain strict separation between patient-facing and account-facing activity: do not share patient-identifiable information with commercial teams, and do not combine the two sides of the role in a single engagement or documentation thread.
  • Operate strictly within approved materials and compliance guardrails.
Desired Qualifications
  • Extensive experience in oncology patient navigation, access and reimbursement, or hub case management.
  • An advanced degree, such as an MBA, Master of Public Health, Doctor of Pharmacy, or another relevant clinical or business degree.
  • An active registered nurse license and a Bachelor of Science in Nursing.
  • Experience using customer relationship management and case-management platforms, preferably Salesforce Health Cloud, to document interactions, manage cases, and maintain accurate records.
  • Verbal, written, and presentation communication skills.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 28th, 2026
GSK Q3 sales rise 5% to $11.3B as specialty medicines drive growth, 2026 guidance reaffirmed

GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, driven by specialty medicines. Core operating profit rose 5%, while core earnings per share rose 1%. The company reaffirmed its 2026 guidance, expecting sales and core operating profit in the upper half of their ranges. Higher interest costs after the $10.6 billion Nuvalent acquisition will hold core earnings per share growth in the lower half of its range. Specialty medicines grew 15%, led by Cabenuva, up 35%. Vaccines sales fell 2% on Shingrix destocking in China. Research and development spending rose 22%. GSK has started 18 phase III studies this year and expects four more. It declared a third-quarter dividend of 17 pence per share.

Yahoo Finance
Oct 28th, 2026
GSK shares slide as pipeline doubts and weak vaccine sales offset $11.3B sales beat

GSK shares fell about 4% on October 28 despite a third-quarter sales and profit beat, as investors focused on pipeline doubts and weak vaccine sales, including shingles shot Shingrix. The stock fell as much as 7.3% earlier in the day. Core profit was 54.6 pence per share on turnover of £8.89 billion, against expectations of 50.4 pence and £8.84 billion. Specialty medicines for HIV, respiratory conditions and cancer rose 15%, but sales of new asthma drug Exdensur and vaccines missed forecasts. Chief executive officer Luke Miels is running a £1.9 billion ($2.5 billion) cost-savings plan to fund drug development ahead of patent losses. Market forecasts for 2031 sales of £36.64 billion trail GSK's target of more than £40 billion. GSK kept its annual outlook and took a £328 million restructuring charge in the quarter.

Yahoo Finance
Oct 28th, 2026
FTSE 100 slips 0.3% ahead of budget as GSK falls 4.3% and Unilever drops 3.4% despite earnings beats

British stocks fell on Wednesday as investors awaited the budget and weighed results from GSK and Unilever. The FTSE 100 was down 0.30% at 08:18 GMT, extending Tuesday's fall. GSK was the top loser, down 4.3%, despite beating third-quarter expectations. Core earnings per share were 54.6 pence against a consensus of 50.4 pence, and revenue was £8.89 billion. Unilever fell 3.38% even after it raised its volume growth forecast to at least 3%. Finance Minister John Healey said he would scrap gas standing charges, which cost the typical household £108 a year. Standard Chartered raised its full-year targets after third-quarter pretax profit jumped 27% to $2.25 billion. Brent futures rose 1.4% to $110.91 a barrel.

Yahoo Finance
Oct 28th, 2026
GSK holds guidance as specialty drugs lift sales 5% to $11.3B, but $417M charge cuts profit 16%

GSK kept its 2026 guidance after specialty medicines drove another quarter of growth, though a £328 million restructuring charge cut its profit. Sales rose 5% at constant exchange rates to £8.9 billion. Core operating profit rose 5% to £3.1 billion, while total operating profit fell 16% to £2.1 billion. The charge relates to Accelerate Growth, a cost-cutting programme that targets £1.9 billion of annual savings by 2029 at a total cost of £2.4 billion. GSK plans to put the savings mainly into research and development. Specialty medicines grew 15% to £3.9 billion, while vaccines fell 2% to £2.6 billion. Net debt rose to £20.7 billion from £14.5 billion at the end of 2025, after the $10.8 billion Nuvalent takeover. Chief executive Luke Miels said GSK had "delivered another strong quarter.

Yahoo Finance
Oct 27th, 2026
GSK's oncology push: Jemperli FDA approval and strong ADC data at ESMO for $97.4B group

GSK presented late-stage oncology data at the ESMO Congress in October 2026 on three drugs: Jemperli, Mo-Rez and Ris-Rez. The £76.7 billion pharmaceuticals group is leaning on oncology as a key part of its mix. The US Food and Drug Administration (FDA) granted Jemperli accelerated approval for MSI-H/dMMR locally advanced rectal cancer. In the AZUR-1 trial, 71% of patients received dostarlimab alone, without additional treatment or progression in the assessment window. Mo-Rez showed a 62% confirmed response rate in platinum-resistant ovarian and endometrial cancers, with a median duration of 12.2 months. Ris-Rez delivered a 61% objective response rate in extensive stage small cell lung cancer. Investors should watch the phase III trials and AZUR-1 follow-up data.